CD38 antibody plus azathioprine for chronic kidney rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your kidney transplant must be at least 6 months old (from a living or deceased donor).
- Your kidney function (eGFR) should be 30 or higher.
- You must have donor-specific antibodies (HLA Class I and/or II).
- A kidney biopsy must show chronic active antibody-mediated rejection (caABMR).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.